This online risk calculator can help clinicians weigh the risks and benefits of ASA for individual patients (calculator).
This cohort of elderly patients discharged from acute care found a higher risk of mortality among those discharged on a PPI versus no PPI. Although only hypothesis generating at this point, this study should give us pause when discharging elderly on PPI therapy (abstract).
The new xTAG GI pathogen panel has been approved by the FDA, which tests for: Bacteria (Campylobacter, C. difficile toxin A/B, E. coli O157, Enterotoxigenic E.coli, Salmonella, Shigella, and Shiga?like Toxin producing E. coli), Viruses (Norovirus and Rotavirus) and Parasites (Cryptosporidium and Giardia) (FDA site).
In this trial of patients with recurrent Cdiff, they were treated with vancomycin, then randomized to no further therapy, duodenal lavage, or duodenal infusion of donor feces. Those in the donor feces group had 81% resolution of disease at 10 weeks (after 1 infusion), compared to 23% of those in the lavage group, and 31% of the vancomycin only group, with no difference in adverse events. This will become the new standard of care for recurrent Cdiff (abstract).
In this trial of patients intubated and receiving tube feedings, they were randomized to measuring gastric residuals or not measuring gastric residuals. Those that did not have their gastric residuals measured had the same risk of VAP, and higher attainment of goal caloric intake, compared to those that did have their residuals measured. This study found no benefit, and potential harm for routinely measuring gastric residuals (abstract).